Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by the cerebral accumulation of amyloid and tau pathology that causes synaptic and neuronal injury leading to progressive dementia. Recently, anti‐amyloid monoclonal antibodies have been shown to reduce cerebral amyloid burden with corresponding slowing of the progression of AD dementia. 1 , 2 Based on these results, the U.S. Food and Drug Administration (FDA) approved lecanemab as a disease‐modifying therapy (DMT) for early symptomatic AD in July 2023, and approved donanemab, also for early symptomatic AD, in July 2024. However, the degree to which these DMTs slow dementia progression is modest and has been deemed by some not to reach minimal clinical importance. 3 Given that therapy with these agents is costly, burdensome, and associated with risk for amyloid‐related neuroimaging abnormalities (ARIA), there has been some reluctance to initiate treatment with these drugs without a clearer demonstration of their clinical benefit. 4
